184 related articles for article (PubMed ID: 32471187)
1. Internalization of Metal-Organic Framework Nanoparticles in Human Vascular Cells: Implications for Cardiovascular Disease Therapy.
Al-Ansari DE; Mohamed NA; Marei I; Zekri A; Kameno Y; Davies RP; Lickiss PD; Rahman MM; Abou-Saleh H
Nanomaterials (Basel); 2020 May; 10(6):. PubMed ID: 32471187
[No Abstract] [Full Text] [Related]
2. Studies on metal-organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension.
Mohamed NA; Abou-Saleh H; Kameno Y; Marei I; de Nucci G; Ahmetaj-Shala B; Shala F; Kirkby NS; Jennings L; Al-Ansari DE; Davies RP; Lickiss PD; Mitchell JA
Sci Rep; 2021 Feb; 11(1):4336. PubMed ID: 33619326
[TBL] [Abstract][Full Text] [Related]
3. Degradation and Erosion of Metal-Organic Frameworks: Comparative Study of a NanoMIL-100 Drug Delivery System.
Vuong MDL; Horbenko Y; Frégnaux M; Christodoulou I; Martineau-Corcos C; Levitz P; Rollet AL; Gref R; Haouas M
ACS Appl Mater Interfaces; 2024 Jan; 16(2):2086-2100. PubMed ID: 38166380
[TBL] [Abstract][Full Text] [Related]
4. NanoMIL-100(Fe) containing docetaxel for breast cancer therapy.
Rezaei M; Abbasi A; Varshochian R; Dinarvand R; Jeddi-Tehrani M
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1390-1401. PubMed ID: 28838252
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Metal-Organic Framework MIL-89 nanoparticles toxicity on embryonic zebrafish development.
Al-Ansari DE; Al-Badr M; Zakaria ZZ; Mohamed NA; Nasrallah GK; Yalcin HC; Abou-Saleh H
Toxicol Rep; 2022; 9():951-960. PubMed ID: 35875258
[TBL] [Abstract][Full Text] [Related]
6. Metal Organic Framework (MOF) Particles as Potential Bacteria-Mimicking Delivery Systems for Infectious Diseases: Characterization and Cellular Internalization in Alveolar Macrophages.
Guo A; Durymanov M; Permyakova A; Sene S; Serre C; Reineke J
Pharm Res; 2019 Feb; 36(4):53. PubMed ID: 30790066
[TBL] [Abstract][Full Text] [Related]
7. Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy.
Mohamed NA; Davies RP; Lickiss PD; Ahmetaj-Shala B; Reed DM; Gashaw HH; Saleem H; Freeman GR; George PM; Wort SJ; Morales-Cano D; Barreira B; Tetley TD; Chester AH; Yacoub MH; Kirkby NS; Moreno L; Mitchell JA
Pulm Circ; 2017; 7(3):643-653. PubMed ID: 28447910
[TBL] [Abstract][Full Text] [Related]
8. Increased Thermal Conductivity in Metal-Organic Heat Carrier Nanofluids.
Nandasiri MI; Liu J; McGrail BP; Jenks J; Schaef HT; Shutthanandan V; Nie Z; Martin PF; Nune SK
Sci Rep; 2016 Jun; 6():27805. PubMed ID: 27302196
[TBL] [Abstract][Full Text] [Related]
9. Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases.
Mohamed NA; Marei I; Crovella S; Abou-Saleh H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163328
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities.
Yang P; Ren J; Yang L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982284
[TBL] [Abstract][Full Text] [Related]
11. Metal-Based Nanoparticles for Cardiovascular Diseases.
Scafa Udriște A; Burdușel AC; Niculescu AG; Rădulescu M; Grumezescu AM
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256075
[TBL] [Abstract][Full Text] [Related]
12. Hierarchical superparamagnetic metal-organic framework nanovectors as anti-inflammatory nanomedicines.
Zhao H; Sene S; Mielcarek AM; Miraux S; Menguy N; Ihiawakrim D; Ersen O; Péchoux C; Guillou N; Scola J; Grenèche JM; Nouar F; Mura S; Carn F; Gazeau F; Dumas E; Serre C; Steunou N
J Mater Chem B; 2023 Apr; 11(14):3195-3211. PubMed ID: 36951043
[TBL] [Abstract][Full Text] [Related]
13. Biocompatible porous metal-organic framework nanoparticles based on Fe or Zr for gentamicin vectorization.
Unamuno X; Imbuluzqueta E; Salles F; Horcajada P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2018 Nov; 132():11-18. PubMed ID: 30179739
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle: A Promising Player in Nanomedicine and its Theranostic Applications for the Treatment of Cardiovascular Diseases.
Saeed S; Ud Din SR; Khan SU; Gul R; Kiani FA; Wahab A; Zhong M
Curr Probl Cardiol; 2023 May; 48(5):101599. PubMed ID: 36681209
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease.
Frąk W; Wojtasińska A; Lisińska W; Młynarska E; Franczyk B; Rysz J
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009488
[TBL] [Abstract][Full Text] [Related]
16. Current Advances in Nanotheranostics for Molecular Imaging and Therapy of Cardiovascular Disorders.
Setia A; Mehata AK; Priya V; Pawde DM; Jain D; Mahto SK; Muthu MS
Mol Pharm; 2023 Oct; 20(10):4922-4941. PubMed ID: 37699355
[TBL] [Abstract][Full Text] [Related]
17. Cellular Uptake, Intracellular Trafficking, and Stability of Biocompatible Metal-Organic Framework (MOF) Particles in Kupffer Cells.
Durymanov M; Permyakova A; Sene S; Guo A; Kroll C; Giménez-Marqués M; Serre C; Reineke J
Mol Pharm; 2019 Jun; 16(6):2315-2325. PubMed ID: 31012592
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of Nano/Microsized MIL-101Cr Through Combination of Microwave Heating and Emulsion Technology for Mixed-Matrix Membranes.
Gruber I; Nuhnen A; Lerch A; Nießing S; Klopotowski M; Herbst A; Karg M; Janiak C
Front Chem; 2019; 7():777. PubMed ID: 31803718
[TBL] [Abstract][Full Text] [Related]
19. Biological drug and drug delivery-mediated immunotherapy.
Xiao Q; Li X; Li Y; Wu Z; Xu C; Chen Z; He W
Acta Pharm Sin B; 2021 Apr; 11(4):941-960. PubMed ID: 33996408
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases.
Yang F; Xue J; Wang G; Diao Q
Front Pharmacol; 2022; 13():999404. PubMed ID: 36172197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
